Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Fidelio Capital in connection with the establishment of its largest fund to date
Mandate

Vinge has advised Fidelio Capital in connection with the establishment of its largest fund to date

June 08, 2023 Employment and Benefits Banking and Finance Corporate Tax Private Funds M&A

The fund – which is Fidelio Capital’s third – has secured more than EUR 1 billion in total capital commitments from an international investor base, which is more than triple the size of the total capital commitments of its previous investment mandate.

Fidelio Capital was founded by Gabriel Fitzgerald in 2010 and focuses on investments in companies without being limited by a pre-determined investment horizon or geographical border, in which it can be an active owner. Through its investment strategy, Fidelio Capital has generated market leading returns, with an average gross IRR of 80% since inception.

Vinge’s team primarily consisted of Mattias Schömer, Jonas Bergström, Jesper Ottergren, Martin Cronsioe, Viveka Classon, Malin Malm Waerme, Fredrik Dahl, Anton Sjökvist, Emelie Svanberg, Semir Omerbasic and Viktoria Wnuk.

 

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025